64,044 Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) Purchased by Northern Trust Corp

Northern Trust Corp bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 64,044 shares of the company's stock, valued at approximately $1,242,000. Northern Trust Corp owned about 0.18% of Oruka Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of ORKA. JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics during the fourth quarter worth approximately $54,000. AlphaCentric Advisors LLC purchased a new position in Oruka Therapeutics during the fourth quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $144,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $303,000. Finally, B Group Inc. acquired a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $388,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock traded up $0.81 during trading on Monday, reaching $11.77. 226,508 shares of the company were exchanged, compared to its average volume of 225,193. Oruka Therapeutics, Inc. has a 52-week low of $5.49 and a 52-week high of $31.13. The company has a market capitalization of $440.68 million, a P/E ratio of -1.88 and a beta of 0.25. The stock's 50 day simple moving average is $9.73 and its two-hundred day simple moving average is $13.61.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. As a group, equities analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. HC Wainwright reissued a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Wolfe Research assumed coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 target price for the company. Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. BTIG Research assumed coverage on Oruka Therapeutics in a report on Thursday, May 22nd. They set a "buy" rating for the company. Finally, Wedbush reissued an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 15th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $40.38.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.